Amyris & Genome Compiler Launch Testing Program for Pharma and Biotech Companies to Explore DNA Construction and Design Solutions

  EMERYVILLE and LOS ALTOS, Calif., (August 10, 2015) -- Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, and Genome Compiler Corp., a synthetic biology platform company, today announced the availability of an open testing program for pharma and biotech companies to explore DNA design and construction solutions. The two companies announced a collaboration agreement in…

Amyris & Genome Compiler Partner to Commercialize DNA Construction Software Services for the Pharma and Biotech Industries

Combination of Amyris’s DNA construction capabilities and Genome Compiler’s computer-aided DNA design software aims to accelerate development of therapeutics   EMERYVILLE and LOS ALTOS, Calif., March 3, 2015 — Amyris, Inc. (Nasdaq:AMRS), an industrial bioscience company, and Genome Compiler Corp., a synthetic biology platform company, have entered into a collaboration agreement to integrate Amyris’s automated lab services with…